Purpose—Symptomatic intracranial hemorrhage (sICH) is the most feared complication of
intravenous thrombolytic therapy in acute ischemic stroke. Treatment of sICH is based on …

Purpose—To critically review and evaluate the science behind individual eligibility criteria
(indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant …

Abstract Background and Purpose Patients with the Coronavirus Disease of 2019 (COVID-
19) are at increased risk for thrombotic events and mortality. Various anticoagulation …

Hemorrhagic stroke comprises about 20% of all strokes, with intracerebral hemorrhage
(ICH) being the most common type. Frequency of ICH is increased where hypertension is …

Hemorrhagic transformation (HT) is a common complication of ischemic stroke that is
exacerbated by thrombolytic therapy. Methods to better prevent, predict, and treat HT are …

Background The aim of the Safe Implementation of Thrombolysis in Stroke-Monitoring Study
(SITS-MOST) was to assess the safety and efficacy of intravenous alteplase as thrombolytic …

Background Most strokes are due to blockage of an artery in the brain by a blood clot.
Prompt treatment with thrombolytic drugs can restore blood flow before major brain damage …

Background and Purpose: Available data on the clinical course of patients with acute
ischemic stroke due to medium vessel occlusion (MeVO) are mostly limited to those with M2 …

Background and Purpose—Symptomatic intracerebral hemorrhage (SICH) is a serious
complication in patients with acute ischemic stroke treated with intravenous thrombolysis …

Background: The existence of cerebral reperfusion injury in human beings remains
controversial. Thus, we aimed to explore the presence of reperfusion injury in acute …